EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis–Associated Pulmonary Arterial Hypertension

Lisa Lim iD, Dylan Hansen, Jessica Fairley iD, Maryam Tabesh, Laura Ross iD, Nava Ferdowsi, Gene-Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, Lauren V Host, Jennifer Walker, Gabor Major iD und 3 weitere

Canadian Respiratory Journal · 2025

DOI: 10.1155/carj/5021789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2025. Verfasst von Lisa Lim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, St. Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, University of Melbourne, Royal Australasian College of Physicians.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Treatment recommendations for systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) have evolved from initial monotherapy to upfront combination therapy with agents, including endothelin receptor antagonists, phosphodiesterase‐5 inhibitors and prostanoids. In the presence of comorbidities, such as heart and lung disease, some clinicians have favoured monotherapy due to concerns about worsening ventilation–perfusion mismatch. We sought to evaluate whether comorbidity burden impacts prescribing practices, quality of life and survival in SSc‐PAH.

Methods

We analysed prospectively collected data from participants recruited to the Australian Scleroderma Cohort Study (ASCS) between 2007 and 2024. Participants were included if they had PAH confirmed by right heart catheterisation. Data were collected on the presence of 12 comorbidities as defined by the Charlson Comorbidity Index (CCI), and prescription of PAH therapies, at PAH diagnosis and each subsequent annual visit. High morbidity was defined as a CCI score ≥ 4. With regard to prescribing practices, subgroup analysis was performed on two groups. The cardiac comorbidity group included patients with a diagnosis of angina, acute myocardial infarction, congestive cardiac failure or hypertension. The pulmonary comorbidity group included those with a diagnosis of chronic obstructive pulmonary disease or asthma. An additional subgroup of patients with SSc‐related interstitial lung disease (ILD) was compared to those without ILD. Survival was evaluated using the Kaplan–Meier method and a multivariable Cox regression model.

Results

Among 2004 patients within the ASCS, 238 patients with SSc‐PAH were included (11.8%). SSc‐PAH patients had significantly higher CCI scores (3.0 vs. 2.0, p < 0.001) and were more likely to have a high morbidity index (30.3% vs. 18.6% p < 0.001). Within the cohort of SSc‐PAH patients, there were no significant differences between high and low morbidity patients with regard to clinical characteristics, autoantibody profile or internal organ manifestation. There was no difference in use of PAH medications between SSc‐PAH patients with a low and high morbidity, with similar proportions receiving combination, monotherapy and no therapy, p = 0.10. This was also the case in a subgroup analysis of those with cardiac comorbidity, pulmonary comorbidity or SSc‐ILD. When comparing SSc‐PAH patients with high morbidity to those without using K‐M survival analysis, there was higher all‐cause mortality ( p = 0.05). Univariable survival analysis showed no significant survival difference between SSc‐PAH patients with high and low comorbidity burden. Combination therapy for PAH was associated with better survival compared to monotherapy (HR 0.60, 95% CI: 0.43–0.84, p = 0.003).

Conclusion

In this large cohort of SSc‐PAH patients, the choice of treatments did not appear to differ based on high comorbidity burden or coexisting pulmonary or cardiac comorbidity, with a majority of SSc‐PAH patients receiving combination therapy. Receiving combination therapy, irrespective of comorbidity status, improved survival in our cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicPulmonary Arterial HypertensionHypertension, PulmonaryHumansFemaleMaleMiddle AgedComorbidityAgedAustraliaQuality of LifeProspective StudiesLung Diseases, Interstitial

Autor:innen und Institutionen

  • Department of Rheumatology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Melbourne, Australia.
  • Department of Rheumatology, Monash Medical Centre, Melbourne, Victoria, Australia.
  • Department of Medicine, Monash University, Melbourne, Australia.
  • Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

ORCID-Profile: Lisa Lim, Jessica Fairley, Laura Ross, Gabor Major, Mandana Nikpour

Förderung

  • National Health and Medical Research Council
  • University of Melbourne
  • Royal Australasian College of Physicians
  • Vincent Fairfax Family Foundation
  • Avant Foundation
  • Australian Government

Zitieren

APA

Lim, L., Hansen, D., Fairley, J., Tabesh, M., Ross, L., Ferdowsi, N., Ngian, G. S., Apostolopoulos, D., Sahhar, J., Host, L. V., Walker, J., Major, G., Proudman, S., Stevens, W., & Nikpour, M. (2025). Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis–Associated Pulmonary Arterial Hypertension. Canadian Respiratory Journal. https://doi.org/10.1155/carj/5021789

Vancouver

Lim L, Hansen D, Fairley J, Tabesh M, Ross L, Ferdowsi N, et al. Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis–Associated Pulmonary Arterial Hypertension. Canadian Respiratory Journal. 2025. doi:10.1155/carj/5021789

BibTeX
@article{Lim2025,
  author = {Lim, Lisa and Hansen, Dylan and Fairley, Jessica and Tabesh, Maryam and Ross, Laura and Ferdowsi, Nava and Ngian, Gene-Siew and Apostolopoulos, Diane and Sahhar, Joanne and Host, Lauren V and Walker, Jennifer and Major, Gabor and Proudman, Susanna and Stevens, Wendy and Nikpour, Mandana},
  title = {Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis–Associated Pulmonary Arterial Hypertension},
  journal = {Canadian Respiratory Journal},
  year = {2025},
  doi = {10.1155/carj/5021789}
}
Kostenlos starten →